ADDITIVE EFFECT OF GENES POLYMORPHISM OF FOLATE CYCLE PROTEINS AND HOMOCYSTEIN LEVEL IN PATIENTS WITH PROLIFERATIVE DISEASES OF THE BREAST AS A POTENTIAL FACTOR OF THE RISK OF THROMBOSSES
https://doi.org/10.21518/2307-1109-2018-2-46-53
Abstract
Aim. The aim of study was to examine the relationship between serum and mammary gland homocysteine levels with the carrier of separate SNP (single nucleotide polymorphism) genes of the folate metabolism system in patients with proliferative diseases and breast cancer. Methods and results. The study included 182 patients with proliferative diseases of the mammary gland in transbaikalia. The control group included 144 women who did not have oncological diseases. The serum homocysteine level and the supernatant of the mammary tissue homogenate were evaluated by high performance liquid chromatography. Genotyping for the detection of polymorphism MTHFRС677T, MTHFRА1298C, MTRA2756G, MTRRA66G was carried out by polymerase chain reaction with the detection of the amplification product in real time. In the course of molecular genetic testing in patients with proliferative diseases of the mammary gland, there was found: 1) the absence of an explicit association of the carriage of genetic polymorphism MTHFRС677T, MTHFRА1298C, MTRA2756G and MTRRA66G with serum homocysteine concentration, however, comparative hyperhomocysteinemia and, to a lesser extent, in women with the benign breast diseases; 2) the highest homocysteine content in the blood in patients with breast cancer whose genotype was characterized by combinations of polymorphic alleles MTR2756G x MTRR66G; 3) that the MTR2756A allele and genotype MTHFR1298AC, especially their combination of MTHFR1298AC x MTR2756A, increase the risk of developing benign breast formations; 4) the effect of the risk alleles MTR2756G and MTRR66GON the concentration of homocystein in the tumor tissue of the mammary gland. Conclusion. These patterns indicate a certain contribution of the polymorphisms studied, especially their additive effect, both in the development of proliferative diseases of the mammary gland and in the possible potentiation of prothrombotic effects in these patients against the background of tumor progression and homocysteine metabolism disorders.
About the Author
Aleksandr V. Markovsky
Federal State Budgetary Institution of Higher education “Chita State Medical Academy” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Markovsky Aleksandr Viktorovich - Junior Researcher, Laboratory of Molecular Genetics, Molecular Medicine Research Institute
tel. (3022) 35-34-78
39A Gorkogo str., Chita, 672000References
1. Brose K.M.J., Lee A.Y.Y. Cancer-associated thrombosis: prevention and treatment. Curr Oncol. 2008; 15(suppl 1): 58–67. PMC2216419.
2. Horsted F., West J., Grainge M.J. Risk of Venous thromboembolism in Patients with Cancer: A systematic Review and Meta-Analysis. PLoS med. 2012; 9(7): e1001275. doi:10.1371/journal.pmed.1001275.
3. Ouyang S., Li Y., Liu Z. et al. Association between MTR A2756G and MTRR A66G polymorphisms and maternal risk for neural tube defects: a meta-analysis. Gene. 2013; 515(2): 308-12. doi:10.1016/j.gene.2012.11.070.
4. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России, 2018. 250 с. ISBN 978-5-85502-234-6. / Malignant tumors in Russia in 2016 (incidence and mortality). ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. M.: FSU P.A. Herzen MnIoI, branch of FSBU P.A. Herzen FMIZ Health care of Russia, 2018. 250 p. ISBN 978-5-85502-234-6.
5. Марковский А.В., Страмбовская Н.Н., Терешков П.П. Молекулярно-генетические и сывороточные маркеры нарушений фолатного обмена у больных пролиферативными заболеваниями и раком молочной железы. Сибирский онкологический журнал. 2017; 16(2): 50–55. doi:10.21294/18144861-2017-16-2-50-55. / Markovsky A.V., Strambovskaya N.N., Tereshkov P.P. Molecular-genetic and serum markers of folate metabolism deficiency in patients with proliferative breast disease and breast cancer. Siberian Journal of Oncology. 2017; 16(2): 50–55. doi:10.21294/18144861-2017-16-2-50-55.
6. Khan U.T., Walker A.J., Baig S. et al. Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis. BMC Cancer. 2017; 17(1): 747. doi:10.1186/s12885-017-3719-1 .
7. Zhloba A.A., Blashko E.L. Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 800(1-2): 275-280. PMID: 14698266.
8. Raijmakers M.T.M., Steegers E.A.P., Peters W.H.M. Glutathione s-transferases and thiol concentrations in embryonic and early fetal tissues. Human reproduction. 2001; 16(11): 2445–2450. PMID: 11679536.
9. Шилова А.Н., Шкода О.С., Ломиворотов В.В. и др. Ассоциация полиморфных вариантов генов метаболизма фолиевой кислоты с риском развития рака легкого, рака предстательной железы, рака молочной железы и рака матки. Российский онкологический журнал. 2017; 22(4): 203-208. doi: 10.18821/1028-9984-2017-22-4-203-208. / Shilova A.N., Shkoda O.S., Lomivorotov V.V. et al. Association of the folate metabolism genes with the risk for lung, prostate, breast and uterine cancer. russian Cancer Journal. 2017; 22(4): 203-208. doi:10.18821/1028-9984-2017-22-4-203-208.
10. Баркаган З.С., Костюченко Г.И., Котовщикова Е.Ф. Гипергомоцистеинемия как самостоятельный фактор риска поражения и тромбирования кровеносных сосудов. Патология кровообращения и кардиохирургия. 2002; 1: 65–71. / Barkagan Z.S., Kostyuchenko G.I., Kotovshchikova E.F. Hyperhomocysteinemia as independent risk factor of blood vessels lesion andthrombosing. Pathology of circulation and heart surgery. 2002; 1: 65–71.
11. Foy P., Moll S. Thrombophilia: 2009 Update. Curr Treat Options Cardio med. 2009; 11(2): 114-128. https://doi.org/10.1007/s11936-009-0012-x.
12. Pasta L., Pasta F., D’Amico M. PAI-1 4G-4G, MtHFR 677tt, V Leiden 506Q, and Prothrombin 20210A in splanchnic Vein thrombosis: Analysis of Individual Patient Data From three Prospective studies. J Clin Exp Hepatol. 2016 Mar; 6(1): 10-4. doi: 10.1016/j.jceh.2015.11.002.
13. Falvella F.S., Cremolini C., Miceli R. et al. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics J. 2017; 17(4): 331-336. doi:10.1038/tpj.2016.22.
14. Zhao M., Wang X. et al. Homocysteine and stroke Risk: Modifying effect of Methylenetetrahydrofolate Reductase C677T Polymorphism and Folic Acid Intervention. Stroke. 2017; 48(5): 1183–1190. doi:10.1161/STROKEAHA.116.015324.
15. Yates Z., Lucock M. Interaction between common folate polymorphisms and B-vitamin nutritional status modulates homocysteine and risk for a thrombotic event. Mol Genet Metab. 2003; 79(3): 201-213. https://doi.org/10.1016/s1096-7192(03)00093-3.
16. Naushad S.M., Jain Jamal M.N., Prasad C.K. Relationship between methionine synthase, methionine synthase reductase genetic polymorphisms and deep vein thrombosis among south Indians. Clin Chem Lab Med. 2008; 46(1): 73-79. doi:10.1515/CCLM.2008.021.
17. Harmon D.L., Shields D.C., Woodside J.V. et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol. 1999; 17(4): 298-309. doi:10.1002/(SICI)1098-2272(199911)17: 4<298: : AID-GePI5>3.0.Co, 2-V.
18. Ray J.G. Hyperhomocysteinemia: no longer a consideration in the management of venous thromboembolism. Curr Opin Pulm Med. 2008; 14(5): 369-373. doi:10.1097/MCP.0b013e328307ee38.
19. Den Heijer M., Lewington S., Clarke R. Homocysteine, MtHFR and risk of venous thrombosis a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005; 3: 292-299. doi:10.1111/j.1538-7836.2005.01141.x.
Review
For citations:
Markovsky A.V. ADDITIVE EFFECT OF GENES POLYMORPHISM OF FOLATE CYCLE PROTEINS AND HOMOCYSTEIN LEVEL IN PATIENTS WITH PROLIFERATIVE DISEASES OF THE BREAST AS A POTENTIAL FACTOR OF THE RISK OF THROMBOSSES. Aterotromboz = Atherothrombosis. 2018;(2):46-53. (In Russ.) https://doi.org/10.21518/2307-1109-2018-2-46-53
Views:
1407
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 